Genomic Health, Inc. (GHDX)
(Delayed Data from NSDQ)
$67.55 USD
+1.67 (2.53%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.63 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$67.55 USD
+1.67 (2.53%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.63 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
AVEO Pharmaceuticals (AVEO) Soars: Stock Adds 11.8% in Session
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) was a big mover last session, as the company saw its shares rise more than 11% on the day amid huge volumes.
Intuitive Surgical (ISRG) Beats on Q2 Earnings & Revenues
by Zacks Equity Research
Strong performance in the Instruments & Accessories as well as Systems segments drove Intuitive Surgical's (ISRG) top line in Q2.
Neogen (NEOG) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Neogen (NEOG) sticks to its four-pronged growth strategy for steady progress. Also, the company's accretive buyouts and its broader international base are a boon.
Can Solid Global Prospects Drive Align's (ALGN) Q2 Earnings?
by Zacks Equity Research
Align Technology (ALGN) poised to gain on continued strength in all geographies in Q2.
Abbott (ABT) Q2 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Abbott (ABT) posts another quarter of strong EPD and Medical Devices performance. Particularly, Abbott has been riding high on a healthy growth within its Diabetes Care business.
Haemonetics Gains on Strong Plasma, Wider Global Footprint
by Zacks Equity Research
Strong growth of Haemonetics' (HAE) plasma-derived biopharmaceuticals is attributable to solid end-market demand.
Is Genomic Health (GHDX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GHDX) Outperforming Other Medical Stocks This Year?
Is Genomic Health (GHDX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GHDX) Outperforming Other Medical Stocks This Year?
Here's Why You Should Hold Onto Opko Health (OPK) Stock Now
by Zacks Equity Research
Opko Health's (OPK) strong focus in R&D bodes well. However, the company faces cutthroat competition in the niche space.
AngioDynamics (ANGO) Q4 Performance Dull, Competition Rife
by Zacks Equity Research
AngioDynamics' (ANGO) fourth-quarter performance dull; stiff competition a serious concern.
Veeva Systems' Development Cloud Platform Picked by Idorsia
by Zacks Equity Research
Switzerland's Idorsia implements Veeva Systems' (VEEV) Development Cloud. Veeva Systems gains foothold in Europe.
J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay
by Zacks Equity Research
The FDA defers decision regarding label expansion application to include cardiovascular indication on the label of J&J's (JNJ) diabetes drug Invokana.
Can Rhythm and Neuro Aid Boston Scientific (BSX) Q2 Earnings?
by Zacks Equity Research
Boston Scientific (BSX) set to ride high on strength in Rhythm and Neuro business in Q2.
Here's Why You Should Add Inogen (INGN) to Your Portfolio
by Zacks Equity Research
Inogen's (INGN) solid product portfolio is a key catalyst. Also, the company benefits from strong focus in Europe.
Here's Why You Should Invest in DaVIta (DVA) Stock Right Now
by Zacks Equity Research
Strong fundamentals and solid international presence make DaVita (DVA) a lucrative pick.
QIAGEN Test-Menu Expansion on Track, Low HPV Sales a Woe
by Zacks Equity Research
QIAGEN's (QGEN) HPV sales in the United States remain tepid. Weak APAC sales are due to bleak applied testing business.
Here's Why You Should Add Edwards Lifesciences (EW) Now
by Zacks Equity Research
We are upbeat about Edwards Lifesciences' (EW) strong transcatheter valve sales in the domestic market as well as overseas.
Here's Why You Should Invest in BioScrip (BIOS) Right Now
by Zacks Equity Research
We are upbeat about BioScrip's (BIOS) progress in the last reported quarter, courtesy of its multi-faceted CORE plan to improve financial position.
Can Medical Devices Strength Drive Abbott (ABT) Q2 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to gain on continued growth in Medical Devices business in Q2.
Achillion's 3rd Factor D Inhibitor Enters Clinical Studies
by Zacks Equity Research
Achillion (ACHN) commences a first-in-human phase I study on ACH-5548, a next-generation, oral small-molecule factor D inhibitor.
Here's Why You Should Hold Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Strong performance by Intuitive Surgical's (ISRG) flagship da Vinci system is a key growth driver. However, the company faces stiff competition in the niche space.
Top Stock Picks for the Week of July 9th
by Panel Of Zacks Experts
Two Outperforming Companies in the Healthcare arena.
Why You Should Add Boston Scientific (BSX) to Your Portfolio
by Zacks Equity Research
Boston Scientific's (BSX) agreement for Cryterion Medical buyout in the field of atrial fibrillation buoys investor optimism on the stock.
Abaxis (ABAX) and Zoetis Merger Deal Crosses HRS Hurdle
by Zacks Equity Research
With the adoption of Abaxis' (ABAX) point-of-care diagnostic instruments post acquisition, the combined entity's veterinary diagnostics category should grow faster than the animal health industry.
Zoetis (ZTS) Tides Over HSR Hurdle for Abaxis Acquisition
by Zacks Equity Research
Zoetis' (ZTS) waiting period under the HSR Act ends. It is related to its proposed merger with Abaxis for a purchase consideration of roughly $2 billion in aggregate.